SCHEMBL4143247

SCHEMBL4143247

NC(=O)c1cccc(F)c1OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.52
▸ KDM1A O60341 3/20 0.51
▸ MAOA P21397 1/20 0.51
▸ MAOB P27338 1/20 0.51
▸ SIRT2 Q8IXJ6 2/20 0.49
▸ PARP10 Q53GL7 2/20 0.49
▸ PARP1 P09874 1/20 0.49
▸ HTT P42858 2/20 0.47
▸ LMNA P02545 2/20 0.47
▸ PARP15 Q460N3 1/20 0.47
▸ HTR1A P08908 1/20 0.46
▸ SLC6A2 P23975 1/20 0.46
▸ SLC6A4 P31645 1/20 0.46
▸ SLC6A3 Q01959 1/20 0.46
▸ MRGPRX4 Q96LA9 1/20 0.46
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ CASP3 P42574 1/20 0.43
▸ RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4153049 0.88 NPC1 (0.55) NPC1KDM1AMAOAMAOBLMNA
SCHEMBL4152542 0.85 KDM1A (0.51) NPC1KDM1AMAOAMAOBHTR1A
SCHEMBL4145578 0.84 ALDH1A1 (0.58) NPC1KDM1AMAOAMAOBHTT
SCHEMBL19730907 0.83 SIRT2 (0.50) NPC1SIRT2PARP10PARP1HTT
SCHEMBL7689226 0.83 PARP1 (0.61) NPC1SIRT2PARP10PARP1HTT
SCHEMBL5313068 0.82 NPC1 (0.50) NPC1KDM1AMAOAMAOBHTT
SCHEMBL28840214 0.82 PARP10 (0.47) NPC1KDM1AMAOAMAOBSIRT2
SCHEMBL1761152 0.82 THRA (0.50) NPC1SIRT2PARP10PARP1HTT
SCHEMBL1667777 0.81 BCAT2 (0.56) SIRT2PARP10PARP1HTTKDM4E
SCHEMBL26942219 0.80 KDM1A (0.61) NPC1KDM1AMAOAMAOBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 — — US disclosed
EP-1951244-A2 CALCILYTIC COMPOUNDS SmithKline Beecham Corporation (US) 2008-08-06 — — EP disclosed
WO-2007062370-A2 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137557-A1 Calcilytic Compounds CALCR, SOST, CALCB NPC1 503/4885KDM1A 4865/4885MAOA 3846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback